<b>Background:</b> From 2019 July 15 to 2022 February 14, the REZOR study enrolled 369 treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring <i>EGFR</i> mutations (exon 19 deletion or L858R mutation). Here, EGFR is linked to non-small cell lung carcinoma.